A Phase 2 interventional study of ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN), sponsored by iCell Gene Therapeutics. Recruiting at 4 sites in United States. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by iCell Gene Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 70th largest by planned enrollment of the 100 interventional ones that give a count, is one of 15 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 28 of the 49 other live ones, and was the 106th registered.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
Fate Therapeutics · Sites in United States
Ages 12–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
iCell Gene Therapeutics is the lead sponsor of 17 studies on the registry; 7 are open to participants now.
iCell Gene Therapeutics has 1 study filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.
Systemic Lupus Erythematosus (SLE) is a multisystem, chronic autoimmune disease that may impact multiple organs including the joints, skin, kidney, heart, brain and lungs, with severity ranging from mild to life-threatening. Lupus Nephritis (LN) is the most prevalent and severe form of SLE with high morbidity and mortality and persistent relapses despite current therapies.
SLE, with or without LN is driven largely by pathogenic autoantibodies produced by CD19 expressing B cells and BCMA expressing plasma cells, including long-lived plasma cells.
ICG318, the investigational agent in this clinical trial is an armored, compound chimeric antigen receptor (CAR) composed of two independently functioning CARs that simultaneously target the B-cell CD19 surface antigen and the plasma cell/ long lived plasma cell BCMA surface antigen.
This study is being conducted to evaluate the safety and efficacy of ICG318 in SLE patients with or without LN, who have not shown adequate clinical response to prior therapies.
A single dose of ICG318 following a lymphodepletion regimen will be evaluated.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
This study's planned enrollment of 20 is below the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Browse Lupus Nephritis studies →iCell Gene Therapeutics is the lead sponsor of 17 studies on the registry; 7 are open to participants now.
Compared within Lupus Nephritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lupus Erythematosus, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biologic drug infusion
Biological: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion
Anti-BCMA, Anti-CD19 Compound CAR-T Cells
Number of Adverse Events after ICG318 infusion
Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESI), and Dose Limiting Toxicities (DLTs).
Time frame: Starting day 0 and up to 1 year after ICG318 infusion.
DORIS remission rate
DORIS remission defined as no circulating autoantibodies (e.g. dsDNA, Smith etc.) detected, no SLE medications, and SLEDAI-2K score of 0-1 (down from severe 7-10).
Time frame: Starting day 0 and assessed at 6 months, and 1 year after ICG318 infusion.
Determine the recommended phase 2 dose (RP2D) regimen.
The protocol is based on cohort schema with dose escalation from 0.5x10\^6/kg to 4x10\^6/kg.
Time frame: Starting day 0 and assessed 1 year after ICG318 infusion.
Cmax
Maximum serum concentration of ICG318.
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
Tmax
Time to maximum serum concentration of ICG318.
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
T1/2
Half-life of ICG318 serum concentration.
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
AUC
Plasma ICG318 concentration versus time. Total systemic exposure to ICG318 over time.
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
Rate of B cell elimination and naïve B-Cell recovery
B cell subsets will be assessed by flow cytometry panels and B-Cell receptor sequencing.
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
Recovery of immunoglobulins
Immunoglobulins IgG, IgM and IgA levels.
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
SLE Autoantibody levels
Changes in levels of SLE specific autoantibodies (e.g. dsDNA, Smith etc.)
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
Number of patients achieving DORIS remission, LLDAS, Complete or Partial Renal Response (in LN patients)
As per the DORIS and SLEDAI-2K remission criteria.
Time frame: Starting day 0 and assessed at 6 months, and 1 year after ICG318 infusion.
Renal histology
Renal Biopsies will be performed prior to and post-ICG318 infusion.
Time frame: The first biopsy will be obtained prior to ICG318 infusion. Next biopsy will be assessed up to 6 months to 1 year after ICG318 infusion.
Complement levels
Changes in C3 and C4 complement levels in serum.
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
Serum creatinine levels
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
Urine Protein-Creatinine Ratio (uPCR) levels.
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
eGFR value
Time frame: Assessed as per schedule of events up to 1 year after ICG318 infusion.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.
Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
iCell Gene Therapeutics